India, April 24 -- Humacyte Inc. (HUMA), a commercial-stage biotechnology platform company, announced on Friday the realignment of ex-U.S. rights to Symvess, a bioengineered tissue for repairing blood vessels in cases of vascular trauma.
Vascular trauma refers to injuries that damage blood vessels-often caused by accidents, penetrating wounds, or severe limb injuries- and can lead to life-threatening bleeding or loss of limb function if not treated quickly.
The acellular tissue engineered vessel (ATEV) was developed for the treatment of extremity vascular trauma indications. The biologics license application (BLA) for ATEV received approval from the U.S. Food and Drug Administration (FDA) in December 2024.
The company has a distribution ...